Ex Vivo Tumor Fragment Platform

Champions Oncology offers platforms for ex vivo drug testing in tumor cluster cultures derived from our solid and liquid tumor patient-derived xenograft (PDX) models. Utilizing high content imaging and fluorescent-based readouts in 96 and 384-well formats, these platforms enable the rapid development of high throughput ex vivo assays for both traditional and immuno-oncology applications that can enhance early discovery research and de-risk in vivo studies.

Ex Vivo Tumor Fragment Platform - no title

Provided as a customizable platform, researchers can choose warm or cryopreserved tumor fragments based on their needs. Champions' Ex Vivo Tumor Fragment Platform can be used to:

  • Rank multiple agents before progressing to additional studies
  • Validate agent therapeutic targets in a cohort with specific characteristics
  • Study the mechanism of action of an agent
  • Prioritize tumor indications and PDX models for further studies.

Available Platform Endpoints:

  • CellTiter-Glo® (standard readout)
  • High-Content Imaging
  • Western Blot
  • RT-PCR
  • Luminex/ELISA
  • NGS
  • Proteomics
Ex VivoTumor Fragment Platform WebPage CTA